{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:53:18Z","timestamp":1781639598464,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharmaceuticals","award":["Novartis Pharmaceuticals"],"award-info":[{"award-number":["Novartis Pharmaceuticals"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617 is a radioligand therapy targeting cells expressing prostate-specific membrane antigen (PSMA). The pharmacokinetics, dosimetry, and safety of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617 in participants with metastatic castration-resistant prostate cancer are described previously. In this study, we describe the blood pharmacokinetics behavior, biodistribution, and dosimetry of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617 to support its clinical use in Chinese participants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nine participants were infused with\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617 (range: 6985.6\u20138036.0 MBq). The geometric (Geo)-mean blood terminal half-life was 52.6\u00a0h, corresponding to an effective half-life of approximately 40\u00a0h. The Geo-mean maximum blood concentration of 11.3 ng\/mL was achieved at a median time of 0.217\u00a0h post administration. The Geo-mean volume of distribution and clearance were 123\u00a0L and 1.62\u00a0L\/h, respectively. The lacrimal glands received the highest absorbed dose of 3.1 mGy\/MBq (Geo-coefficient of variation, 93.7%), followed by the thyroid, kidneys, and salivary glands. The Geo-mean whole-body effective dose was 890 mSv (Geo-coefficient of variation, 112.4%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The blood pharmacokinetics and organ dosimetry of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617 in Chinese participants with progressive metastatic castration-resistant prostate cancer were consistent with those previously reported. The cumulative absorbed dose, corresponding to six cycles of treatment, was consistent with published literature. This analysis was conducted as part of a phase II study registered as NCT05670106 at ClinicalTrials.gov on November 7, 2022.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-026-01401-3","type":"journal-article","created":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T15:55:08Z","timestamp":1772380508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase II study evaluating pharmacokinetics and dosimetry of 177Lu-PSMA-617 radioligand therapy in Chinese participants with progressive metastatic castration-resistant prostate cancer"],"prefix":"10.1186","volume":"16","author":[{"given":"Hongcheng","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runqin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2781-7753","authenticated-orcid":false,"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,1]]},"reference":[{"issue":"6","key":"1401_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1401_CR2","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353.","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"1401_CR3","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1186\/s12885-022-10244-9","volume":"22","author":"Q Huang","year":"2022","unstructured":"Huang Q, Zi H, Luo L, Li X, Zhu C, Zeng X. Secular trends of morbidity and mortality of prostate, bladder, and kidney cancers in China, 1990 to 2019 and their predictions to 2030. BMC Cancer. 2022;22(1):1164.","journal-title":"BMC Cancer"},{"key":"1401_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.853623","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang F, Wang C, Xia H, Lin Y, Zhang D, Yin P, et al. Burden of prostate cancer in China, 1990\u20132019: findings from the 2019 Global Burden of Disease Study. Front Endocrinol (Lausanne). 2022;13:853623.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1401_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115966","volume":"263","author":"G Capasso","year":"2024","unstructured":"Capasso G, Stefanucci A, Tolomeo A. A systematic review on the current status of PSMA-targeted imaging and radioligand therapy. Eur J Med Chem. 2024;263:115966.","journal-title":"Eur J Med Chem"},{"issue":"4","key":"1401_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76(4):469\u201378.","journal-title":"Eur Urol"},{"key":"1401_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00623","volume":"8","author":"MC Hupe","year":"2018","unstructured":"Hupe MC, Philippi C, Roth D, Kumpers C, Ribbat-Idel J, Becker F, et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol. 2018;8:623.","journal-title":"Front Oncol"},{"key":"1401_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.630589","volume":"11","author":"PJ Vlachostergios","year":"2021","unstructured":"Vlachostergios PJ, Niaz MJ, Sun M, Mosallaie SA, Thomas C, Christos PJ, et al. Prostate-specific membrane antigen uptake and survival in metastatic castration-resistant prostate cancer. Front Oncol. 2021;11:630589.","journal-title":"Front Oncol"},{"issue":"4","key":"1401_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517\u201323.","journal-title":"J Nucl Med"},{"issue":"2","key":"1401_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2214\/AJR.18.20845","volume":"213","author":"MP Yadav","year":"2019","unstructured":"Yadav MP, Ballal S, Sahoo RK, Dwivedi SN, Bal C. Radioligand therapy with (177)Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2019;213(2):275\u201385.","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"1401_CR11","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2967\/jnumed.119.236414","volume":"61","author":"J Violet","year":"2020","unstructured":"Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of (177)Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61(6):857\u201365.","journal-title":"J Nucl Med"},{"issue":"12","key":"1401_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"10","key":"1401_CR13","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.2967\/jnumed.121.262305","volume":"63","author":"J O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue J, Zanzonico P, Humm J, Kesner A. Dosimetry in radiopharmaceutical therapy. J Nucl Med. 2022;63(10):1467\u201374.","journal-title":"J Nucl Med"},{"issue":"12","key":"1401_CR14","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.3390\/biomedicines10123020","volume":"10","author":"S van der Gaag","year":"2022","unstructured":"van der Gaag S, Bartelink IH, Vis AN, Burchell GL, Oprea-Lager DE, Hendrikse H. Pharmacological optimization of PSMA-based radioligand therapy. Biomedicines. 2022;10(12):3020. https:\/\/doi.org\/10.3390\/biomedicines10123020.","journal-title":"Biomedicines"},{"issue":"5","key":"1401_CR15","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s00259-024-06640-x","volume":"51","author":"C Stokke","year":"2024","unstructured":"Stokke C, Gnesin S, Tran-Gia J, Cicone F, Holm S, Cremonesi M, et al. EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials. Eur J Nucl Med Mol Imaging. 2024;51(5):1268\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1401_CR16","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"K Sjogreen Gleisner","year":"2022","unstructured":"Sjogreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778\u2013809.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1401_CR17","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57(8):1170\u20136.","journal-title":"J Nucl Med"},{"issue":"2","key":"1401_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4274\/mirt.08760","volume":"26","author":"L Kabasakal","year":"2017","unstructured":"Kabasakal L, Toklu T, Yeyin N, Demirci E, Abuqbeitah M, Ocak M, et al. Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: stability, bio-distribution and dosimetry. Mol Imaging Radionucl Ther. 2017;26(2):62\u20138.","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"1","key":"1401_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MNM.0000000000000606","volume":"38","author":"MP Yadav","year":"2017","unstructured":"Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, et al. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Nucl Med Commun. 2017;38(1):91\u20138.","journal-title":"Nucl Med Commun"},{"issue":"1","key":"1401_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2967\/jnumed.123.265448","volume":"65","author":"K Herrmann","year":"2024","unstructured":"Herrmann K, Rahbar K, Eiber M, Sparks R, Baca N, Krause BJ, et al. Renal and multiorgan safety of (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the VISION dosimetry substudy. J Nucl Med. 2024;65(1):71\u20138.","journal-title":"J Nucl Med"},{"issue":"7","key":"1401_CR21","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s00259-009-1072-6","volume":"36","author":"F Forrer","year":"2009","unstructured":"Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36(7):1138\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1\u20132","key":"1401_CR22","first-page":"25","volume":"36","author":"International Commission on Radiological Protection","year":"2006","unstructured":"International Commission on Radiological Protection. Human alimentary tract model for radiological protection. ICRP Publication 100. A report of The International Commission on Radiological Protection. Ann ICRP. 2006;36(1\u20132):25\u2013327. iii.","journal-title":"Ann ICRP"},{"issue":"4","key":"1401_CR23","first-page":"102S","volume":"40","author":"SR Thomas","year":"1999","unstructured":"Thomas SR, Stabin MG, Chen CT, Samaratunga RC. MIRD pamphlet no. 14 revised: a dynamic urinary bladder model for radiation dose calculations. J Nucl Med. 1999;40(4):102S-23S.","journal-title":"J Nucl Med"},{"key":"1401_CR24","unstructured":"The 2007 Recommendations of the International Commission on Radiological Protection. Ann ICRP. 2007;37(2\u20134):1\u2013332. ICRP Publication 103."},{"issue":"3","key":"1401_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","volume":"43","author":"H Bergsma","year":"2016","unstructured":"Bergsma H, Konijnenberg MW, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course. Eur J Nucl Med Mol Imaging. 2016;43(3):453\u201363.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"1401_CR26","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","volume":"43","author":"H Bergsma","year":"2016","unstructured":"Bergsma H, Konijnenberg MW, van der Zwan WA, Kam BL, Teunissen JJ, Kooij PP, et al. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging. 2016;43(10):1802\u201311.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"1401_CR27","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.2967\/jnumed.108.053173","volume":"49","author":"BW Wessels","year":"2008","unstructured":"Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, et al. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response\u2013implications for radionuclide therapy. J Nucl Med. 2008;49(11):1884\u201399.","journal-title":"J Nucl Med"},{"issue":"10","key":"1401_CR28","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1177\/0022034509343143","volume":"88","author":"O Grundmann","year":"2009","unstructured":"Grundmann O, Mitchell GC, Limesand KH. Sensitivity of salivary glands to radiation: from animal models to therapies. J Dent Res. 2009;88(10):894\u2013903.","journal-title":"J Dent Res"},{"key":"1401_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X17745203","volume":"5","author":"BA Howard","year":"2017","unstructured":"Howard BA, James OG, Perkins JM, Pagnanelli RA, Borges-Neto S, Reiman RE. A practical method of I-131 thyroid cancer therapy dose optimization using estimated effective renal clearance. SAGE Open Med Case Rep. 2017;5:2050313X17745203.","journal-title":"SAGE Open Med Case Rep"},{"issue":"1","key":"1401_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/0167-8140(91)90067-Q","volume":"22","author":"JG Letschert","year":"1991","unstructured":"Letschert JG, Gonzalez Gonzalez D, Oskam J, Koornneef L, van Dijk JD, Boukes R, et al. Results of radiotherapy in patients with stage I orbital non-Hodgkin\u2019s lymphoma. Radiother Oncol. 1991;22(1):36\u201344.","journal-title":"Radiother Oncol"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01401-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01401-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01401-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:07:30Z","timestamp":1781636850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01401-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1401"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01401-3","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was completed in compliance with the Declaration of Helsinki and Good Clinical Practice Guidelines. The trial protocol was approved by the Medical Ethics Committees of Fudan University Zhongshan Hospital, Beijing Cancer Hospital, and the First Affiliated Hospital of Guangzhou Medical University, and the Ethics Committees of Sun Yat-sen University Cancer Center and Clinical Trial, West China Hospital of Sichuan University. Informed consent was obtained from all participants, and all participant data were deidentified for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HS, JG, WF, YL, RH, QD, ZY, YY, XW, DG, LH, ZJi, FW, DX, JW, and DY have no disclosures to report. ZJiang, HL, JL, RL, and LQ are employees of Novartis Pharmaceuticals and holders of Novartis stock.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}